Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
GE HealthCare secures CE mark for MINItrace Magni cyclotron
GE HealthCare has secured CE Mark certification for its MINItrace Magni cyclotron and broadened its PETtrace Solid Target Platform to …
-
Merz concludes enrolment in Phase III Xeomin trials for migraine
Merz Therapeutics has concluded patient enrolment in MINT-C and MINT-E, two global Phase III clinical trials assessing Xeomin (incobotulinumtoxinA) for …
-
Transcripta Bio, Mayo Clinic join force on ALS therapies
Transcripta Bio has entered into a research collaboration and licensing agreement with Mayo Clinic to identify potential treatments and therapeutic …
-
FDA approves Stryker’s Sonopet 3 surgical platform
The US Food and Drug Administration (FDA) has granted 510(k) clearance to Stryker for Sonopet 3, the medical technology company's …
-
Alentis and PinotBio partner to develop claudin-1 oncology ADCs
Alentis Therapeutics and PinotBio have entered into a research collaboration and licensing agreement to develop claudin-1-targeting antibody-drug conjugates (ADCs) for …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Pilatus doses first patient in Phase I PLT012 trial for HCC
Pilatus Biosciences has dosed the first patient in Hong Kong, as part of an ongoing Phase I clinical trial assessing …
-
Butterfly Medical secures EU MDR certification for BPH implant
Israel-based Butterfly Medical has secured European Union Medical Device Regulation (EU MDR 2017/745) certification for its Butterfly Prostatic Retraction Device. The …
-
Dosing completed in Calluna Pharma’s Phase II AURORA trial
Calluna Pharma has completed patient dosing in its Phase II AURORA trial of CAL101 to treat idiopathic pulmonary fibrosis (IPF). The …
-
Pfizer partners with Enodia Therapeutics in $500m drug deal
Pfizer and Enodia Therapeutics have announced a research collaboration and licensing deal potentially worth over $500m to discover and develop …
-
Southern Research secures NIH funding for drug testing hub
Southern Research has secured an $8m grant from the US National Institutes of Health (NIH) to establish a national shared-use …
-
Tortugas’ Phase IIb schizophrenia trial of obuprazine meets primary endpoint
Tortugas Neuroscience and its partner Hansoh Pharma have reported that their Phase IIb clinical trial of obuprazine (TRTL-107) for acute …
-
First patient treated in Spiro’s PULSAR asthma trial
Spiro Medical has treated the first patient in its PULSAR feasibility study evaluating neuromodulation for severe, uncontrolled asthma. The clinical-stage medical …
-
Perceptive, Nucleus partner to support radiopharmaceutical development
Perceptive Discovery and Nucleus RadioPharma have announced a non-exclusive strategic partnership to assist radiopharmaceutical developers shift from initial target validation through …
-
FDA grants 510(k) clearance for Urolution Medical’s OpenFlo catheter
The US Food and Drug Administration (FDA) has granted 510(k) clearance for Urolution Medical’s OpenFlo urinary catheter. Cleared for adult use, …
-
Perceive Bio concludes Phase IIa trial enrolment for GA
Perceive Biotherapeutics (Perceive Bio) has concluded enrolment ahead of targets in its Phase IIa JOURNEY clinical study evaluating VOY-101, an …
